Lynn Marks

Dr. Marks is a consultant (Senior R&D Advisor) across a range of projects and challenges faced by BARDA. He particularly focuses on the emerging CARB-X portfolio and program. He joined BARDA in September 2017.

Dr. Marks recently retired, after 25 years, from GlaxoSmithKline (GSK) as Senior Vice President in R&D. He was Senior Clinical Advisor for Infectious Diseases and, in addition, Chief Research Practices Officer across the Pharmaceutical, Vaccines and Consumer Healthcare R&D organizations. Further, over the years he has supported the National Center for the Advancement of Translational Sciences within the National Institutes of Health (NCATS/NIH). He has joined the NCATS Advisory Council and will serve as Co-Chair of the Cures Acceleration Network.
Dr. Marks’ career began with a faculty position at the University of South Alabama College of Medicine in the Infectious Diseases Division where he held teaching and patient care responsibilities as well as a NIH funded Physician Scientist Award. Subsequently he joined, what is now GSK, in the Infectious Diseases organization with increasing accountability over time. Ultimately he led the Infectious Diseases Therapy area globally. Over the next decade, his portfolio of accountability spread across antivirals, including a large portfolio of anti-HIV medications, diseases of the developing world (malaria and tuberculosis), as well as, anti-bacterials with a focus on multi-drug resistant pathogens. Subsequently, he transitioned to lead Projects, Clinical Platforms & Sciences. In this role, he had operational accountability for clinical trials over a broad scope of disease and therapeutic areas on a global scale ranging across the Phase I to IV development landscape. He was accountable for more than 3,000 employees in over 50 countries.
In addition, he helped create TransCelerate BioPharma, Inc. (TBI) where he served as Corporate Secretary and Chair of the portfolio Oversight Committee. TBI is a not for profit Industry Collaboration focused on improving quality, efficiency and the well being of patients involved in clinical trials globally.
Dr. Marks is Board Certified in Internal Medicine and Infectious Diseases.